Literature DB >> 12565833

Rapid disappearance of deoxyribose-1-phosphate in platelet derived endothelial cell growth factor/thymidine phosphorylase overexpressing cells.

M de Bruin1, K Smid, A C Laan, P Noordhuis, M Fukushima, K Hoekman, H M Pinedo, G J Peters.   

Abstract

Platelet derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) catalyzes the phosphorolysis of thymidine (TdR) to thymine and deoxyribose-1-phosphate (dR-1-P) and has a pro-angiogenic effect for which dR-1-P may be responsible. Using a purine nucleoside phosphorylase based assay it was found that TdR incubation did not increase dR-1-P accumulation in colon cancer cell line Colo320 and its PD-ECGF/TP transfected variant Colo320TP1. The assay was linear up to 25,000pmol dR-1-P with complete recovery of dR-1-P from cellular extracts. There was a huge discrepancy between thymine production and the measured dR-1-P level, 0.05% of the expected value for dR-1-P was found, indicating that there was a rapid disappearance of dR-1-P. However, in cellular extracts, TdR incubation increased dR-1-P, measurable by trapping, which was inhibited by a thymidine phosphorylase inhibitor. dR-1-P directly added to cellular extracts disappeared within 5-10min. In conclusion, large amounts of dR-1-P are produced by Colo320TP1 cells, which rapidly disappear thus not resulting in a net accumulation of dR-1-P in these cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12565833     DOI: 10.1016/s0006-291x(03)00022-6

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  Transition state analysis of the arsenolytic depyrimidination of thymidine by human thymidine phosphorylase.

Authors:  Phillip A Schwartz; Mathew J Vetticatt; Vern L Schramm
Journal:  Biochemistry       Date:  2011-02-03       Impact factor: 3.162

2.  Synthesis and in vitro evaluation of 5-fluoro-6-[(2-iminopyrrolidin-1-YL)methyl]uracil, TPI(F): an inhibitor of human thymidine phosphorylase (TP).

Authors:  John R Grierson; J Scott Brockenbrough; Janet S Rasey; Linda Wiens; Hubert Vesselle
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2010-01       Impact factor: 1.381

3.  Glycation of glutamate cysteine ligase by 2-deoxy-d-ribose and its potential impact on chemoresistance in glioblastoma.

Authors:  Donald S Backos; Kristofer S Fritz; Debbie G McArthur; Jadwiga K Kepa; Andrew M Donson; Dennis R Petersen; Nicholas K Foreman; Christopher C Franklin; Philip Reigan
Journal:  Neurochem Res       Date:  2013-06-07       Impact factor: 3.996

4.  Thymidine kinase 1 and thymidine phosphorylase expression in non-small-cell lung carcinoma in relation to angiogenesis and proliferation.

Authors:  J Scott Brockenbrough; Janice K Morihara; Stephen E Hawes; Joshua E Stern; Janet S Rasey; Linda W Wiens; Qinghua Feng; Hubert Vesselle
Journal:  J Histochem Cytochem       Date:  2009-08-03       Impact factor: 2.479

5.  The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients.

Authors:  M Tampellini; A Saini; I Alabiso; R Bitossi; M P Brizzi; C M Sculli; A Berruti; G Gorzegno; A Magnino; E Sperti; S Miraglia; L Forti; O Alabiso; M Aglietta; A Harris; L Dogliotti
Journal:  Br J Cancer       Date:  2006-06-13       Impact factor: 7.640

Review 6.  The dual role of thymidine phosphorylase in cancer development and chemotherapy.

Authors:  Annelies Bronckaers; Federico Gago; Jan Balzarini; Sandra Liekens
Journal:  Med Res Rev       Date:  2009-11       Impact factor: 12.944

7.  4-Methylumbelliferone inhibits ovarian cancer growth by suppressing thymidine phosphorylase expression.

Authors:  Ryosuke Tamura; Yoshihito Yokoyama; Hidemi Yoshida; Tadaatsu Imaizumi; Hideki Mizunuma
Journal:  J Ovarian Res       Date:  2014-10-11       Impact factor: 4.234

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.